Wide Ranks

ALKS

Alkermes plc

29.32

Top Statistics
Market Cap 4 B Forward PE 16.56 Revenue Growth -0.70 %
Current Ratio 3.45 Trailing PE 12.80 Earnings Growth 102.60 %
Profit Margins 22.15 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 11.71 Enterprise / Revenue 2.79 Price To Sales Trailing12 Months 3.15
Profitability
Profit Margins 22.15 % Operating Margins 27.70 %
Balance Sheet
Total Cash 908 M Total Cash Per Share 5.62 Total Debt 366 M
Total Debt To Equity 28.33 Current Ratio 3.45 Book Value Per Share 7.99
All Measures
Short Ratio 909.00 % Message Board Id finmb_24572 Shares Short Prior Month 15 M
Return On Equity 0.2923 City Dublin Uuid 292fcc8e-3551-3f1c-b4a6-cd1ad786bd09
Previous Close 29.25 First Trade Date Epoch Utc 679 M Book Value 7.99
Beta 0.4350 Total Debt 366 M Volume 876887
Price To Book 3.67 Last Split Date 958 M Fifty Two Week Low 22.90
Total Cash Per Share 5.62 Total Revenue 1 B Shares Short Previous Month Date 1 B
Target Median Price 36.00 Audit Risk 1 Max Age 86400
Recommendation Mean 2.00 Sand P52 Week Change 0.3133 Operating Margins 27.70 %
Target Mean Price 34.08 Net Income To Common 386 M Short Percent Of Float 0.1528
Implied Shares Outstanding 161 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 1 M Average Volume10days 1 M Total Cash 908 M
Next Fiscal Year End 1 B Revenue Per Share 9.03 Held Percent Insiders 0.0132
Ebitda Margins 23.84 % Trailing PE 12.80 Date Short Interest 1 B
Most Recent Quarter 1 B Share Holder Rights Risk 2 Regular Market Previous Close 29.25
Target Low Price 21.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 27.97
Open 29.15 Free Cashflow 162 M Dividend Yield 0.00 %
Return On Assets 0.0898 Time Zone Short Name EST Board Risk 5
Trailing Eps 2.29 Day Low 28.63 Address1 Connaught House
Shares Outstanding 161 M Compensation Risk 2 Price Hint 2
Target High Price 43.00 Website https://www.alkermes.com 52 Week Change 0.2146
Average Volume 1 M Earnings Quarterly Growth 93.40 % Forward Eps 2.01
Recommendation Key buy Compensation As Of Epoch Date 1 B Quick Ratio 281.90 %
Last Split Factor 2:1 Regular Market Day High 29.48 Is_sp_500 False
Profit Margins 22.15 % Debt To Equity 28.33 Fifty Two Week High 32.88
Day High 29.48 Shares Short 16 M Regular Market Open 29.15
Industry Key drug-manufacturers-specialty-generic Earnings Growth 102.60 % Enterprise To Revenue 2.79
Revenue Growth -0.70 % Shares Percent Shares Out 0.1024 Operating Cashflow 355 M
Currency USD Time Zone Full Name America/New_York Market Cap 4 B
Is_nasdaq_100 False Zip D04 C5Y6 Quote Type EQUITY
Industry Drug Manufacturers - Specialty & Generic Long Name Alkermes plc Overall Risk 2
Regular Market Day Low 28.63 Held Percent Institutions 1.14 Current Price 29.32
Address2 1 Burlington Road Dublin 4 Enterprise To Ebitda 11.71 Financial Currency USD
Current Ratio 3.45 Gross Margins 83.17 % Industry Disp Drug Manufacturers - Specialty & Generic
Number Of Analyst Opinions 13 Country Ireland Float Shares 153 M
Two Hundred Day Average 26.63 Governance Epoch Date 1 B Ir Website http://investor.alkermes.com/phoenix.zhtml?c=92211&p=irol-irhome
Price To Sales Trailing12 Months 3.15 Enterprise Value 4 B Forward PE 16.56
Regular Market Volume 876887 Ebitda 358 M Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally.

It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.

Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder.

It has collaboration agreements primarily with Janssen Pharmaceutica N.

V.

, Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International.

The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products.

Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.